Use of antibody drug conjugate

To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. The present invention provides an anti-TROP2 antibody having CDRH1 comprising the amino acid sequence represented by SEQ ID No. 23, CDRH2 comprising the amino acid sequenc...

Full description

Saved in:
Bibliographic Details
Main Authors TAKAHASHI, SHU, YAMAGUCHI, MIKI, HAMADA, HIROFUMI, OKAJIMA, DAISUKE, HASEGAWA, JUN, AGATSUMA, TOSHINORI
Format Patent
LanguageChinese
English
Published 16.11.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. The present invention provides an anti-TROP2 antibody having CDRH1 comprising the amino acid sequence represented by SEQ ID No. 23, CDRH2 comprising the amino acid sequence represented by SEQ ID No. 24, and CDRH3 comprising the amino acid sequence represented by SEQ ID No. 25 in the heavy chain variable region; and CDRL1 comprising the amino acid sequence represented by SEQ ID No. 26, CDRL2 comprising the amino acid sequence represented by SEQ ID No. 27, and CDRL3 comprising the amino acid sequence represented by SEQ ID No. 28 in the light chain variable region.
AbstractList To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. The present invention provides an anti-TROP2 antibody having CDRH1 comprising the amino acid sequence represented by SEQ ID No. 23, CDRH2 comprising the amino acid sequence represented by SEQ ID No. 24, and CDRH3 comprising the amino acid sequence represented by SEQ ID No. 25 in the heavy chain variable region; and CDRL1 comprising the amino acid sequence represented by SEQ ID No. 26, CDRL2 comprising the amino acid sequence represented by SEQ ID No. 27, and CDRL3 comprising the amino acid sequence represented by SEQ ID No. 28 in the light chain variable region.
Author HASEGAWA, JUN
AGATSUMA, TOSHINORI
YAMAGUCHI, MIKI
OKAJIMA, DAISUKE
TAKAHASHI, SHU
HAMADA, HIROFUMI
Author_xml – fullname: TAKAHASHI, SHU
– fullname: YAMAGUCHI, MIKI
– fullname: HAMADA, HIROFUMI
– fullname: OKAJIMA, DAISUKE
– fullname: HASEGAWA, JUN
– fullname: AGATSUMA, TOSHINORI
BookMark eNrjYmDJy89L5WSQCy1OVchPU0jMK8lMyk-pVEgpKk1XSM7PyypNTyxJ5WFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8SHhRgZGxiYmRubGjsbEqAEAv1smOw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID TW202344273A
GroupedDBID EVB
ID FETCH-epo_espacenet_TW202344273A3
IEDL.DBID EVB
IngestDate Fri Jul 26 04:46:11 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_TW202344273A3
Notes Application Number: TW202312127350
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231116&DB=EPODOC&CC=TW&NR=202344273A
ParticipantIDs epo_espacenet_TW202344273A
PublicationCentury 2000
PublicationDate 20231116
PublicationDateYYYYMMDD 2023-11-16
PublicationDate_xml – month: 11
  year: 2023
  text: 20231116
  day: 16
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies DAIICHI SANKYO COMPANY, LIMITED
SAPPORO MEDICAL UNIVERSITY
RelatedCompanies_xml – name: SAPPORO MEDICAL UNIVERSITY
– name: DAIICHI SANKYO COMPANY, LIMITED
Score 3.6371894
Snippet To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. The present invention provides...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Use of antibody drug conjugate
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231116&DB=EPODOC&locale=&CC=TW&NR=202344273A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMbNMMbNITDTRBdZWxromFklGupZJlpagwjDNLMnMyMgyEbzK18_MI9TEK8I0gokhC7YXBnxOaDn4cERgjkoG5vcScHldgBjEcgGvrSzWT8oECuXbu4XYuqhBe8fAxoqhoZmai5Ota4C_i7-zmrOzbUi4ml8QWM7EBFhXOzIzsAKb0eag3OAa5gTalVKAXKW4CTKwBQBNyysRYmCqyhBm4HSG3bwmzMDhC53wBjKhea9YhEEutDhVIT9NARgUmUn5KZUKKUWl6QrA7mxWKWgoTJRB0c01xNlDF2hRPNxX8SHhCDcZizGwAHv7qRIMCpbmpokp5uAtzokmZskGSakWZhbATGRpZJCYapBkKskghdscKXyS0gxcIA5oI52hmQwDS0lRaaossEYtSZIDBwUADcN4LA
link.rule.ids 230,309,783,888,25576,76882
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsJAcIJoxJuiBlGxJqa3xra0S_fQGGlLqkIhpgi3pkuLwsES2sbo1zvdFPGit81OMrs7yTx3HgA3hEbECENNQm3VljSDqRJllBbCcE4YUVUa8ixfj7hj7XGqTyuw3NTC8D6hH7w5InLUDPk94_J6tQ1i2Ty3Mr1lC9xK7nq-aYuld4zGiqIQ0e6azmhoDy3Rskx_InrPHKZpqKvvd2AXTWyjmHbgvHSLqpTVb5XSO4S9EWJ7z46g8vVWh5q1mbxWh_1B-eGNy5L30mNojdNYSOYCkmLBkuhTiNb5q4Du7DIvQmEncN1zfMuV8KDg51WBP9neqX0KVfT24wYItKOHUYeXOIcamcksNoiBTERVOYxlpp9B8288zf-AV1Bz_UE_6D94T-dwUACKojqFXEA1W-fxJWrXjLU4Wb4B17Z7HA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Use+of+antibody+drug+conjugate&rft.inventor=TAKAHASHI%2C+SHU&rft.inventor=YAMAGUCHI%2C+MIKI&rft.inventor=HAMADA%2C+HIROFUMI&rft.inventor=OKAJIMA%2C+DAISUKE&rft.inventor=HASEGAWA%2C+JUN&rft.inventor=AGATSUMA%2C+TOSHINORI&rft.date=2023-11-16&rft.externalDBID=A&rft.externalDocID=TW202344273A